Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2019-08-01 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2019-08-01 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 30, 2019, reporting the issuance of a press release announcing financial results for the three and six months ended June 30, 2019. The text explicitly states that the press release is furnished as an exhibit and that the Form 8-K itself is a current report, not the full financial report. The document is short (3797 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the classification rules, such a document announcing initial quarterly financial results is best classified as an Earnings Release (ER).
2019-07-30 English
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text describes an acquisition (merger) of Ab Initio Biotherapeutics by Ligand Pharmaceuticals, including details about the transaction and strategic rationale. There are no financial statements or detailed financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a proxy, earnings release, or other categories. The key content is about a merger/acquisition event, which fits the M&A Activity (TAR) category. The document length is 4528 characters, which is sufficient to contain substantive information about the transaction, not just an announcement of a report. Therefore, the correct classification is M&A Activity (TAR).
2019-07-24 English
PRIMARY DOCUMENT
Director's Dealing
2019-07-03 English
PRIMARY DOCUMENT
Director's Dealing
2019-07-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a description of a new commercial platform license and services agreement with Millennium Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company. It details the terms of the agreement, including fees and royalties, and describes the OmniAb platform technology. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a transcript, proxy, or governance report. It is an announcement of a material event related to licensing and commercial agreements, which fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories. The document length is 4863 characters, which is sufficient for a substantive announcement but does not contain financial statements or detailed financial analysis. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-07-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.